Metraipolis › archive › dc_68d9bcd7d212

Trial design considerations in the face of overdispersion and time-varying event rates: a meta-regression approach with an application in asthma — arXiv:2610.21432

Source
arXiv (en)
Original
https://arxiv.org/abs/2610.21432
License (as archived)
CC0-1.0
Archived
2026-10-16T10:25:49.485Z
SHA-256 of the archived text
651b968084d813db9e77599f0a5f64964fd11a73df764126fa5a88262893c6c4
Stable URL of this page
https://metraipolis.com/documento/dc_68d9bcd7d212

How to cite

Trial design considerations in the face of overdispersion and time-varying event rates: a meta-regression approach with an application in asthma — arXiv:2610.21432 — arXiv (en), https://arxiv.org/abs/2610.21432 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_68d9bcd7d212 (Metraipolis archive dc_68d9bcd7d212, sha256 651b968084d813db9e77599f0a5f64964fd11a73df764126fa5a88262893c6c4)
BibTeX
@misc{dc68d9bcd7d212,
  title = {Trial design considerations in the face of overdispersion and time-varying event rates: a meta-regression approach with an application in asthma — arXiv:2610.21432},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2610.21432},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_68d9bcd7d212; sha256 651b968084d813db9e77599f0a5f64964fd11a73df764126fa5a88262893c6c4},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2610.21432. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

**Purpose:** Relative changes in event rates are a common primary endpoint in confirmatory asthma trials. Reliable assumptions about baseline event rates and extra-Poisson variability are essential for sample size planning. We synthesize placebo-group exacerbation data, evaluate calendar-time trends, and assess implications for trial design. **Methods:** We systematically reviewed randomized controlled trials reporting recurrent asthma exacerbations and extracted control-group outcomes classified by placebo type or asthma severity. Hierarchical negative binomial models accommodated heterogeneous reporting formats and jointly modeled event rates and overdispersion. We compared separate subgroup models with covariate-based models and used meta-regression to adjust for calendar-time trends. Trial design implications were illustrated using the NAVIGATOR trial. **Results:** Sixty-two trials met the inclusion criteria. The estimated relative change in annualized exacerbation rates was -1.8% per year (95% CrI: -7.5%, 4.3%), corresponding to a 16.5% decrease per decade (95% CrI: -54.2%, 52.2%). Substantial between-study heterogeneity in event rates and overdispersion was observed. Within-trial overdispersion was estimated as 1.53 (95% CrI: 0.60, 2.83). In an illustrative phase III design scenario, sample size requirements were sensitive to the target subgroup and uncertainty in the predicted event rate and overdispersion. **Conclusion:** Event rates in clinical trials exhibit considerable heterogeneity and potential temporal variation, and overdispersion is a critical design parameter. Comprehensive modelling of recurrent-event endpoints allows for evidence-based and robust sample size calculations and trial design.

Tema degli esploratori: statistica e scienza dei dati (elenco arXiv stat.ME, nuovi lavori del giorno).
Categorie arXiv: Applications (stat.AP) ; Methodology (stat.ME).
Pagina del lavoro: https://arxiv.org/abs/2610.21432 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-16T08:49:02.696Z dalla pagina https://arxiv.org/list/stat.ME/new (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).